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 Expression of Invasion-Related Extracellular 
Matrix Molecules in Human Glioblastoma Versus 
Intracerebral Lung Adenocarcinoma Metastasis 
and, with rare exceptions, do not metastasize 
outside the brain  [5,  24,  26] . In contrast, carcino-
mas, which often metastasize to the brain, are 
more signifi cantly and sharply delineated from 
the surrounding brain tissue, infi ltrate only short 
distances, and invade as groups of cells rather 
than as single cells  [4] . Consequently, successful 
total surgical resection of metastatic tumors of 
the brain can be achieved in many cases, whereas 
this is usually not possible for primary invasive 
brain tumors. 
 The ECM constitutes a considerable proportion 
of normal brain volume. There is much evidence 
that ECM components can modulate brain tumor 
growth, proliferation, and invasion by many dif-
ferent mechanisms  [6] . The ECM is composed 
mainly of hyaluronan (HA), proteoglycans (PGs), 
and tenascin  [12] . To allow cell adhesion and 
migration, the ECM components interact with 
specifi c receptors on the cell membrane, such as 
integrins, CD44, or CD168. Some proteases and 
 Introduction 
 ▼ 
 During malignant transformation, invasiveness is 
determined by complex functions of tumor cells 
of distinct histological types. A three-step model 
of invasion has been applied to a variety of malig-
nant cell types. Tumor cells at the invasive site 1) 
detach from the growing primary tumor mass; 2) 
adhere to the extracellular matrix (ECM) via spe-
cifi c receptors; and 3) locally degrade the ECM 
components, forming a pathway for neoplastic 
cells to migrate into the surrounding tissue  [51] . 
 Malignant gliomas are the most common pri-
mary brain tumors. They are associated with the 
shortest survival time because of their infi ltra-
tive invasion of the normal brain, which makes 
complete removal of these tumors practically 
impossible. Invasive primary brain tumors are 
almost invariably fatal, recurring close to the 
resection margin in almost all cases. Primary 
brain tumors have a strong tendency to invade 
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 Abstract 
 ▼ 
 Tumor cell invasion into the surrounding brain 
tissue is mainly responsible for the failure of rad-
ical surgical resection, with tumor recurrence in 
the form of microdisseminated disease. Extracel-
lular matrix (ECM)-related molecules and their 
receptors predominantly participate in the inva-
sion process, including cell adhesion to the sur-
rounding microenvironment and cell migration. 
The extent of infi ltration of the healthy brain by 
malignant tumors strongly depends on the tumor 
cell type. Malignant gliomas show much more 
intensive peritumoral invasion than do meta-
static tumors. In this study, the mRNA expression 
of 30 invasion-related molecules (twenty-one 
ECM components, two related receptors, and 
seven ECM-related enzymes) was investigated 
by quantitative reverse transcriptase-polymer-
ase chain reaction. Fresh frozen human tissue 
samples from glioblastoma (GBM), intracerebral 
lung adenocarcinoma metastasis, and normal 
brain were evaluated. Signifi cant diﬀ erences 
were established for 24 of the 30 molecules. To 
confi rm our results at the protein level, immu-
nohistochemical analysis of seven molecules was 
performed (agrin, neurocan, syndecan, versican, 
matrix metalloproteinase 2 [MMP-2], MMP-9, 
and hyaluronan). Determining the diﬀ erences 
in the levels of invasion-related molecules for 
tumors of diﬀ erent origins can help to identify 
the exact molecular mechanisms that facilitate 
peritumoral infi ltration by glioblastoma cells. 
These results should allow the selection of tar-
get molecules for potential chemotherapeutic 
agents directed against highly invasive malig-
nant gliomas.  
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synthases also strongly infl uence invasiveness because of their 
capacity to alter the actual levels of the ECM molecules or to 
degrade the pericellular network  [4] . 
 To understand the evident diﬀ erences between glioblastoma 
(GBM) and intracerebral metastasis, we compared the mRNA 
expression of 30 invasion-related molecules in GBM and intrac-
erebral bronchial adenocarcinoma metastases. To analyze their 
relationship to the environment, the same expression patterns 
were also determined in normal brain tissue. For morphological 
information and to check whether or not diﬀ erences in mRNA 
expression appear on a post-translational level, immunohisto-
chemical analyses were performed for seven molecules (agrin, 
neurocan, syndecan, versican, matrix metalloproteinase 2 
[MMP-2], MMP-9, and HA). 
 Material and Methods 
 ▼ 
 Tissue samples 
 Thirty tissue samples were collected during neurosurgical oper-
ations. The samples were frozen promptly after removal on the 
surface of liquid nitrogen and stored at  – 80   °  C until processing. 
Each sample was collected from a diﬀ erent patient. Eleven pieces 
of infi ltrated margins of GBMs, ten pieces of intracerebral lung 
adenocarcinoma metastases, and nine normal brain tissue sam-
ples taken from epilepsy surgery were carefully selected by an 
experienced neuropathologist for further investigation. Sections 
for histological analysis and immunohistochemistry were cut 
from the same samples used for the mRNA assays. The fresh fro-
zen tissue samples were provided by the Neurosurgical Tissue 
and Tumor Bank of the Neurosurgical Department of our univer-
sity. All procedures were approved by the Ethical Committee 
and every patient signed an informed consent form. 
 RNA analysis 
 The mRNA expression of 30 ECM-related molecules was deter-
mined by real-time quantitative reverse transcriptase-polymer-
ase chain reaction (RT – PCR): 21 PGs, three diﬀ erent MMPs, three 
hyaluronan synthases (HASs), chondroitinase ABC, and the two 
cell membrane receptors CD44 and CD168. Tumor markers (glial 
fi brillary acidic protein [GFAP], carcinoembryonic antigen [CEA], 
and cytokeratins 18 and 19) and the proliferation marker Ki-67, 
were also tested. 
 Fresh-frozen tissue samples were fi rst pulverized with a manual 
CryoPress device (Microtec Co., Japan) precooled in liquid N 2 . 
The powdered still-frozen tissue was then scraped into the 
appropriate volume of TriReagent (Invitrogen, USA) and homo-
genized instantly with a rotor-stator homogenizer. Total RNA 
was isolated from the TriReagent lysates according to the manu-
facturer ’ s instructions. RNA purity and quantity were assessed 
on a NanoDrop  ®  ND-1000 spectrophotometer (NanoDrop Tech-
nologies, USA) and then stored at  – 80   °  C. RNA quality was 
checked on 1.2  % agarose gel stained with ethidium bromide. 
Total RNA was converted to single-stranded cDNA with the 
High-Capacity cDNA Archive Kit with RNasin (Applied Biosys-
tems, USA) using 600  ng of total RNA per sample in one reverse 
transcription reaction. The cDNA transcribed from 100  ng of 
total RNA was loaded per port of the microfl uidic card. 
 TaqMan Low Density Array (TLDA) experiments were performed 
using the Applied Biosystems 7  900  HT real-time PCR system 
with the Micro Fluidic Card upgrade (Applied Biosystems, USA). 
The Micro Fluidic Card format allowed the analysis of 40 genes 
per sample, and each sample was analyzed in duplicate. The 
Micro Fluidic Cards were analyzed with the SDS 2.1 software as 
relative quantifi cation studies (maximum 10 cards per study) 
with automatic threshold settings, and the C T values were 
exported for further analysis. Each 40-gene set contained three 
diﬀ erent assays for housekeeping genes:  β -actin (ACTB),  β 2 -
microglobulin (B 2 M), and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH). ACTB and GAPDH showed the least variation 
among the samples and were used as the reference genes to cal-
culate the dCt value for each gene. 
 Expression values were calculated using the comparative C T 
method, as described previously  [23] . Briefl y, assuming that the 
PCR eﬃ  ciency for any gene on the TLDA is close to 1, mRNA 
expression  [15] for a given gene in the tumor or normal 
 (calibrator) sample can be compared using the simplifi ed 
 equations  [17] : 
 
X tumor  =  2  – dCTtumor and X normal  =  2  – dCTnormal 
 2  – dCT values are the input expression values during further 
 analy sis with GeneSpring 7.3 software (Silicon Genetics, Red-
wood City, CA, USA). Instead of calculating the expression values 
(2  – ddCT ) relative to those of the normal samples, this allowed 
inspection of individual mRNA expression (X) diﬀ erences within 
sample categories. To identify genes with signifi cantly diﬀ erent 
expression levels between diﬀ erent sample groups Mann-Whit-
ney  U -test was performed. Signifi cance was established at 
 p  <  0.05. 
 Immunohistochemistry 
 After evaluating the results of the mRNA determination seven 
molecules were selected and investigated at the protein level 
with immunohistochemistry: agrin, neurocan, syndecan, versi-
can, MMP-2,   −  9, and hyaluronan. 
 Frozen and stored (  −  80   °  C) samples were fi xed in Saint Marie ’ s 
fi xative  [37,  44] for 24  h at 4   °  C. After fi xation and dehydration, 
the tissue samples were embedded in wax, and 5  μ m sections 
were cut. The sections were stained with hematoxylin-eosin and 
immunohistochemical reactions were carried out according to 
the following protocol. Slides were preincubated in ready-to-use 
(2.5  % ) normal horse serum (Vector, Burlingame, CA, USA) for 
30  min at 37   °  C to prevent nonspecifi c binding of the primary 
antibodies. The sections were then incubated overnight at 4   °  C 
with the appropriately diluted antibodies. To promote the mor-
phological evaluation a supplementary section for immunohis-
tochemical and routine hemalaun staining was also performed. 
 The immunohistochemical and HA reactions were visualized 
with the avidin-biotin-peroxidase complex, and the peroxidase 
was detected with a solution containing the H 2 O 2 substrate and 
the diaminobenzidine (DAB) chromogen (ImmPress Reagent Kit, 
Vector; Peroxidase Substrate DAB Kit, Vector). Finally, the nuclei 
were labeled with hemalaun staining, and the sections were 
mounted in DePeX (BDH Laboratory Supplies, Poole, UK). To 
control for the specifi city of the immunohistochemical reac-
tions, sections were treated with the same protocol, excluding 
the primary antibodies, which were replaced with nonimmune 
IgG (Sigma, St Louis, MO, USA) solution at the optimal dilution 
for the diﬀ erent primary antibodies. HA was detected with a 
biotinylated HA-binding complex probe (bHABC), which con-
tains the hyaluronan-binding G1 domain of the cartilage PG, 
aggrecan, and link protein, which have high aﬃ  nity and specifi -
city for HA  [42] . The bHABC probe was kindly provided by 
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R. Tammi and M. Tammi (Institute for Biomedicine, Department 
of Anatomy, University of Kuopio, Kuopio, Finland). The probe 
was used at a concentration of 5  μ g / mL, and the reaction was 
performed as described previously  [9] . 
 The reactions were evaluated by three diﬀ erent investigators 
experienced in histology on a score of 1 – 5 in three diﬀ erent 
locations: intracellular, cell-membrane, and extracellular 
regions, which were evaluated separately for morphological 
information. The scores of the regions were then summed for 
general comparison. 
 Results 
 ▼ 
 Thirty tissue samples were investigated from three diﬀ erent 
homogeneous groups of tissues: eleven GBM samples originat-
ing from the infi ltrated margins of the tumor, ten intracerebral 
lung adenocarcinoma metastases, and nine normal brain tissues. 
The results of the statistical analysis for diﬀ erences in mRNA 
expression levels of 34 molecules between the investigated sam-
ple groups are summarized in   ● ▶  Table 1 . 
 mRNA expression level 
 The mRNA expression of the tumor markers and the Ki67 
 proliferation marker confi rmed the histological diagnosis. The 
mRNA expression of the investigated molecules is illustrated 
in   ● ▶  Fig. 1 . 
 GBM versus normal brain 
 The expression of mRNAs for agrin, fi bronectin, laminin  α -4,  β -1 
and  β -2, perlecan, syndecan-1, tenascin-C, CD44, CD168, HAS-2, 
MMP-2 and -9 was signifi cantly elevated in GBM relative to that 
in the normal brain, whereas the mRNA expression of syndecan-
4, tenascin-R and HAS-1 was statistically lower in the GBM. The 
mRNA levels of aggrecan, brevican, laminin  α -1, -2, laminin  β -1, 
laminin  γ -1, matrilin-1 and -2, neurocan, neuroglycan, synde-
can-2, versican, chondroitinases, HAS-3, and MMP-8 did not dif-
fer signifi cantly between normal brain and GBM. 
 Intracerebral lung adenocarcinoma metastases versus 
normal brain 
 Signifi cantly reduced mRNA expression of brevican, laminin  α -1, 
matrilin-2, neurocan, neuroglycan-C, syndecan-2, tenascin-R, 
and HAS-1 was detected in lung adenocarcinoma metastases 
compared with that in normal brain. Conversely, the expression 
of agrin, fi bronectin, laminin  β -1,  β -2 and  γ -1, perlecan, synde-
can-1 and -4, CD168 and MMP-9  mRNAs was statistically ele-
vated in the metastatic tumor relative to that in normal brain. 
There was no apparent diﬀ erence in the expression of aggrecan, 
laminin  α -2, -4, matrilin-1, tenascin-C, versican, CD44, chon-
 Table 1  Signifi cant diﬀ erences (bold) in the mRNA expression levels of 30 invasion-related molecules and fi ve tumor markers in glioblastoma (GBM), 
 intracere bral lung adenocarcinoma metastasis (Met), and normal brain tissues (Norm). 
  Norm  – Met  Norm  – GBM  GBM  – Met 
  p-value  fold change  p-value  fold change  p-value  fold change 
 aggrecan  0.421  0.79  0.421  0.39  1.000  2.01 
 agrin  0.002  0.30  0.012  0.44  0.218  0.67 
 brevican   <  0.001  172.46  0.820  1.27   <  0.001  135.66 
 fi bronectin   <  0.001  0.08   <  0.001  0.09  0.916  0.87 
 laminin alfa-1  0.032  4.55  0.548  2.98  0.421  1.53 
 laminin alfa-2  0.310  1.84  0.841  0.82  0.222  2.24 
 laminin alfa-4  0.713  0.85  0.023  0.47  0.098  1.79 
 laminin beta-1  0.020  0.36  0.001  0.27  0.379  1.33 
 laminin beta-2  0.020  0.44  0.005  0.34  0.130  1.29 
 laminin gamma-1  0.016  0.29  0.222  0.38  1.000  0.76 
 matrilin-1  0.548  1.69  0.310  2.34  1.000  0.72 
 matrilin-2  0.002  6.07  0.761  0.90   <  0.001  6.72 
 neurocan   <  0.001  44.76  0.095  2.29  0.001  19.50 
 neuroglycan-C   <  0.001  46.94  0.058  3.15   <  0.001  14.89 
 perlecan   <  0.001  0.08   <  0.001  0.12  0.342  0.70 
 syndecan-1   <  0.001  0.01  0.008  0.23   <  0.001  0.06 
 syndecan-2  0.008  3.27  1.000  1.44  0.151  2.27 
 syndecan-4  0.020  0.41  0.048  1.53  0.008  0.27 
 tenascin-C  0.348  0.40  0.006  0.06  0.007  6.91 
 tenascin-R   <  0.001  136.10   <  0.001  10.53  0.018  12.92 
 versican  0.596  1.27  0.289  0.56  0.307  2.29 
 CD44  0.094  0.39  0.003  0.15  0.012  2.70 
 CD168   <  0.001  0.06   <  0.001  0.12  0.053  0.46 
 chondroitinases (AC.ABC)  0.222  0.77  0.841  0.95  0.690  0.81 
 hyaluronan synthase-1   <  0.001  26.98   <  0.001  33.55  0.504  0.80 
 hyaluronan synthase-2  0.838  0.77  0.002  0.11  0.003  6.84 
 hyaluronan synthase-3  0.421  1.75  0.690  0.83  0.222  2.10 
 MMP-2  0.131  0.37  0.004  0.15  0.032  3.08 
 MMP-8  1.000  0.89  0.857  1.50  0.310  0.60 
 MMP-9  0.001  0.06   <  0.001  0.05  0.805  1.11 
 cytokeratin 18  0.008  0.002  0.310  0.72  0.008  0.003 
 cytokeratin 19  0.008  0.003  0.151  4.49  0.008  0.001 
 GFAP  0.016  33.31  0.548  0.73  0.008  45.61 
 Ki67  0.008  0.01  0.008  0.01  0.548  0.82 
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droitinases, HAS-2, -3, MMP-2 and -8 transcripts between the 
two types of tissue. 
 GBM versus intracerebral lung adenocarcinoma 
metastases 
 In a comparison of the anaplastic tumors of diﬀ erent origins, the 
mRNA expression of brevican, matrilin-2, neurocan, neurogly-
can-C, tenascin-C and R, CD44, HAS-2 and MMP-2 was signifi -
cantly higher in GBM compared to lung adenocarcinoma 
metastases. The transcripts of syndecan-1 and syndecan-4 were 
signifi cantly elevated in the intracerebral adenocarcinoma. We 
detected no statistically signifi cant diﬀ erences in agrin, aggre-
can, fi bronectin, laminin  α -1,-2 or -4, laminin  β -1, -2, laminin 
 γ -1, matrilin-1, perlecan, syndecan-2, versican, CD168, chon-
droitinase, HAS-1 and -3, or MMP-8, and -9 transcripts. 
 Immunohistochemistry 
 The immunohistochemical and HA histochemical reactions are 
summarized in   ● ▶  Fig. 2 . According to the morphological evalua-
tion, immunoreactivity for agrin, neurocan, syndecan, and versi-
can was most intense mainly on the cell membrane and in the 
extracellular space, whereas the MMPs showed strong immuno-
reactivity on the cell membrane and intracellularly. Most intense 
immunostaining of agrin, syndecan and MMP-9 was observed in 
the lung adenocarcinoma metastases, while MMP-2, neurocan 
and hyaluronan showed the highest values in GBM samples. The 
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 Fig. 1  mRNA expression of 30 invasion-related 
molecules, tumor markers and Ki67 proliferation 
marker in glioblastoma (GBM), intracerebral lung 
adenocarcinoma metastasis (Met), and normal brain 
(Norm). Relation between mRNA expression of 
each molecule (fold change) in normal brain and in 
metastasis ( a ); normal brain and GBM ( b ); GBM and 
metastasis ( c ). 
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staining intensity of tumor markers and Ki-67 was in accordance 
with the histology. 
 Discussion 
 ▼ 
 Gliomas are the most common primary intracranial tumors. The 
incidence of brain metastasis is about double the number of pri-
mary brain tumors, and more than half of them originate from 
lung cancer  [11] . Both tumor types are anaplastic, dediﬀ erenti-
ated neoplasms, but their biological behaviour and thus their 
therapeutic management diﬀ ers considerably. The unambigu-
ous ability of high grade gliomas to invade normal neural tissue 
makes them diﬃ  cult to control and makes complete surgical 
resection almost impossible. This also explains the extremely 
high mortality associated with anaplastic gliomas. In contrast, 
the invasiveness of intracerebral metastases of anaplastic tumors 
is much more moderate, and radical surgical removal can be 
achieved in most cases. 
 The extracellular matrix plays a pivotal role in the tumorous 
infi ltration of the surrounding tissue. The presence and func-
tions of hyaluronic acid, PGs, synthetic and lytic enzymes, and 
specifi c adhesion receptors have already been intensively inves-
tigated to clarify the molecular mechanisms of invasion, and a 
positive correlation has been established many times 
 [4,  17,  18,  22,  31,  39] . 
 To identify the molecules that are probably responsible for the 
distinct invasiveness of high-grade gliomas and metastatic 
tumors, the mRNA expression of 30 invasion-related molecules 
was measured in fresh-frozen neurosurgical tissue samples of 
GBM, intracerebral lung adenocarcinoma metastases, and nor-
mal brain tissue. Based on data from the literature, 21 ECM com-
ponents, seven proteases, the membrane receptor for hyaluronan 
(CD44), and CD168 were selected for quantitative RT – PCR. To 
verify the results of mRNA analysis, immunohistochemical anal-
ysis of seven molecules (agrin, neurocan, syndecan, versican, 
MMP-2, MMP-9, and hyaluronan) was performed. The mRNA 
expression patterns of the analyzed chosen molecules are illus-
trated in   ● ▶  Fig. 1 . 
 Previous studies have described a positive correlation between 
the invasion potential of gliomas and the expression of brevican 
 [10,  46] , fi bronectin  [25,  43] , laminin  [13,  25] , syndecan  [48] , 
tenascin-C  [16,  52] , versican  [32] , MMP-9  [3,  40,  53] , hyaluronan 
 [7] , and CD44  [30,  35,  49] . We also detected signifi cant diﬀ er-
ences in the mRNA profi les of normal brain and GBM for 
fi bronectin, laminin  β -1, perlecan, syndecan-1, -4, tenascin-C, -
R, CD44, CD168, HAS-1, -2, and MMP-2 and -9. There are no rel-
evant data in the literature relating astrocytomas to changes in 
the levels of aggrecan, matrilin, perlecan, neuroglycan-C, neuro-
can, CD168, or chondroitinase. In this study the mRNA expres-
sion of perlecan and CD168 was signifi cantly higher in 
gliobastomas compared to normal brain, while there were no 
evident diﬀ erences between the others. 
 ECM components and invasion-related molecules have also been 
studied in some cases of non-small-cell lung carcinoma. In bron-
chial adenocarcinomas, elevated levels of hyaluronan  [33] , 
fi bronectin  [15,  19] , laminin  [28,  41] , versican  [34] , MMP-9  [3] , 
MMP-2  [8] , and CD44  [21] have been reported, whereas increased 
levels of perlecan, tenascin-C, and syndecan do not correlate 
well with tumor progression  [14,  27,  38] . There are no data sup-
porting a defi nite correlation between agrin, brevican, matrilin, 
neuroglycan-C, neurocan, CD168, chondroitinase, or HAS and 
the tumor behavior of lung adenocarcinoma. Comparing the 
intracerebral lung adenocarcinoma metastases with normal 
brain, we detected a signifi cant diﬀ erence in the mRNA expres-
sion of 18 molecules out of the 30 tested (  ● ▶  Table 1 ). There are 
some molecules that are specifi c for the tissue of origin (e.  g. 
brevican, neurocan, neuroglycan-C in the brain samples), while 
others probably play an important role in peritumoral invasion 
(fi bronectin, syndecan-1, -4, CD168 and MMP-9). But the expla-
nation for the high expression of agrin, laminin  β -1,  β -2, γ-1 and 
perlecan in intracerebral lung adenocarcinoma metastasis 
needs further investigation. 
 The mRNA expression of 11 molecules diﬀ ered signifi cantly 
between GBM and lung adenocarcinoma metastases (  ● ▶  Table 1 ). 
Since brevican, matrilin-2, neurocan, neuroglycan-C and 
tenascin-R had a higher mRNA expression both in normal brain 
and in GBM compared to the metastatic tumors, these molecules 
can be interpreted as specifi c molecules for glial tissues. On the 
other hand, the mRNA expression of tenascin-C, CD44, HAS-1 
and MMP-2 was elevated only in the GBM compared to the met-
astatic tissue. Based on these observations the high level of the 
former molecules might help to understand the role of ECM in 
GBM in avoiding antitumoral reactions of the surrounding brain 
tissue. Furthermore, the role of the latter molecules in the diﬀ er-
ence in invasion eﬀ ectiveness of GBM can be also hypothesized. 
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 Fig. 2  Immunohistochemical (IHC) evaluation of 
four proteoglycans, two matrix metalloproteinases, 
and hyaluronic acid in glioblastoma, intracerebral 
lung adenocarcinoma metastasis (Met), and normal 
brain (Norm). The reactions were evaluated by three 
diﬀ erent investigators experienced in histology 
on a score of 1 – 5 in three diﬀ erent regions. The 
scores of the regions were then summed for general 
comparison. 
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 Lung adenocarcinoma metastases had high expression of synde-
can-1 and -4, but this proved to be insuﬃ  cient for invading the 
peritumoral brain. 
 BEHAB (brain enriched hyaluronan binding) / brevican, a brain-
specifi c chondroitin sulfate PG, shows dramatic upregulation in 
gliomas and it is also upregulated during periods of increased 
glial cell motility during development and following brain injury 
 [29] . Viapiano et  al. established that brevican expression in glio-
mas have a restricted membrane localization, and its presence in 
high-grade gliomas suggests that it may play a signifi cant role in 
glioma progression, making it an important new potential ther-
apeutic target  [45] . We detected no signifi cant diﬀ erence in 
mRNA expression of brevican between the normal brain and 
GBM, thus our data does not support the role of brevican in GBM 
progression. 
 Although the mRNA expression of fi bronectin was found to be 
signifi cantly higher in GBM than in normal brain, it was also 
defi nitely high in lung adenoracinoma metastases as well, so 
that the role of fi bronectin in the diﬀ erent invasion activity of 
the two diﬀ erent tumor types is not supported by our results. 
 Neurocan, a chondroitin-sulphate PG, is involved in the promo-
tion of neurite outgrowth through interaction with heparan-sul-
phate PGs  [1] . We found signifi cantly lower mRNA expression of 
neurocan in the lung adenocarcinoma metastases than in GBM, 
but the highest value was detected in the normal brain, so the 
role of neurocan in the invasion process of GBM is not clear yet. 
Based on our results it could be hypothesized that neurocan 
plays a predominant part in cell diﬀ erentiation and not in cell 
proliferation or migration. The reason might be that neurocan 
promotes normal neurite outgrowth and not tumoral membrane 
processes. Further investigations are needed for a more precise 
explanation. 
 Neuroglycan-C, another chondroitin-sulphate PG, is a ligand of 
epidermal growth factor receptor (EGFR) Erb-B3 and thus plays 
an active role in tumor growth  [2,  20] . The mRNA expression of 
neuroglycan-C was found to be signifi cantly lower in lung adeno-
carcinoma metastases than in the other two groups, but the 
highest value was detected in normal brain, which does not sup-
port its putative role in glioma invasion. 
 Syndecans were previously found to play a part in glioma inva-
sion  [48] . We found the highest mRNA expression of snydecan-1 
and 4 in lung adenocarcinoma metastases and syndecan-2 in 
normal brain. Based on these data we can not determine their 
specifi c role in the extremely high infi ltrative activity of GBM. 
 Tenascin-C is a glycoprotein of the ECM that was reported to be 
positively correlated to glioma invasion  [9,  27] and have a nega-
tive correlation with tumor progression of bronchial adenocarci-
nomas  [14,  27,  38] . Since we also detected a higher mRNS 
expression of tenascin-C in GBM than in lung adenocarcinoma 
metastases, and it was low again in normal brain, a specifi c role 
of tenascin-C in glioma invasion can be strongly hypothesized. 
 Versican is one of the most common ECM components in the 
brain and plays a role in neurite outgrowth, cell attachment and 
EGFR-mediated signal pathways  [50] . Its elevated expression in 
gliomas has been described previously  [32] . We detected ele-
vated mRNA expression of versican in GBM compared to lung 
adenocarcinoma metastases and normal brain, but the diﬀ er-
ence was not confi rmed stastically. 
 The positive correlation between CD44 and glioma grading and 
the functional connection between HA and CD44 has been 
reported many times  [30,  35,  49] , and a similar association is also 
known with regard to lung adenocarcinomas  [22] . In our study 
we detected signifi cantly elevated CD44  mRNS expression in 
GBM compared to lung adenocarcinoma metastases with a low 
CD44  mRNS expression in normal brain, indicating that CD44 
may play an important role in the invasion process of malignant 
gliomas. HAS-2 also showed increased mRNA expression in GBM 
compared to lung adenocarcinoma metastases or normal brain, 
and immunostaining of HA was most intensive in GBM. These 
observations emphasize the common function of CD44 and 
HAS-2 in tumor infi ltration of the surrounding brain. 
 The role of metalloproteinases in tumor invasion and their rep-
resentative subtypes in gliomas and bronchial adenocarcinomas 
has already been described  [3,  8,  40,  53] . Our observation that 
mRNA expression of MMP-2 is signifi cantly higher in GBM than 
in lung adenocarcinoma metastases and normal brain defi nitely 
underlines its role in the diﬀ erent invasiveness of the two diﬀ er-
ent tumor types. The immunostaining profi le of MMP-2 was in 
accordance with the results of the investigations into mRNA 
expression. 
 Comparison of mRNA expression and 
immunohistochemical fi ndings 
 To investigate the appearance of the diﬀ erent mRNA expressions 
on a post-translational level and obtain morphological informa-
tion, immunohistochemical analyses were performed for seven 
molecules (agrin, neurocan, syndecan, versican, matrix metal-
loproteinase 2 [MMP-2], MMP-9, and HA). 
 The changes in the intensity of immunostaining between the 
three tissue sample groups correlated well with the changes in 
mRNA expression for versican, agrin, syndecan and MMP-2 
(  ● ▶  Fig. 2 ). In immunohistochemical analysis, agrin, syndecan 
and MMP-9 were predominant in bronchial adenocarcinoma, 
whereas MMP-2, neurocan and hyaluronan showed the greatest 
intensity of immunostaining in GBM. 
 Interestingly, the highest staining intensity and mRNA expres-
sion of agrin was detected in the metastasis group. Agrin is an 
important component of the blood-brain barrier  [36,  47] , but its 
presence and role in intracerebral lung adenocarcinoma metas-
tases has not yet been clarifi ed. 
 MMP-9 showed the strongest immunostaining intensity in lung 
adenocarcinoma metastases, but its highest mRNA expression 
was measured in GBM. The highest mRNA expression of neuro-
can was detected in normal brain, but immunohistochemistry 
showed a slightly increased staining intensity in the tumors. 
These fi ndings are probably attributable to post-transcriptional 
events, but further investigation is required. 
 HA was found to be mostly present in GBM. Since the mRNA 
expression of its receptor CD44 was also highest in GBM, their 
common role in the invasion process can be aﬃ  rmed. 
 Conclusions 
 ▼ 
 By comparing the mRNA expression of 30 invasion-related mol-
ecules in GBM, normal brain, and intracerebral lung adenocarci-
noma metastasis, some molecules that probably play a role in 
the extremely high invasive activity of GBM could be identifi ed. 
Based on these results, tenascin-C, CD44, and MMP-2 seem to be 
predominantly involved in peritumoral infi ltration by GBM, but 
a clear role of fi bronectin and syndecans in the diﬀ erent infi ltra-
tive activity of these tumors could not be confi rmed. Adding 
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new data to previous observations, the levels of brevican, neuro-
can, neuroglycan-C and matrilin-2 were also shown to diﬀ er sig-
nifi cantly between lung adenocarcinoma metastasis and GBM. 
 Because ECM components, proteases, and their receptors have 
been shown to play an important role in tumor cell migration 
and invasion, each identifi ed component could be investigated 
further as a potential target for anticancer therapy. 
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